<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741167</url>
  </required_header>
  <id_info>
    <org_study_id>HIPEC 2015-0529</org_study_id>
    <nct_id>NCT02741167</nct_id>
  </id_info>
  <brief_title>Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy</brief_title>
  <official_title>Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the dynamics of inflammatory parameters in presence or
      absence of infectious complications after cytoreductive surgery with hyperthermic
      intraperitoneal chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is the treatment of
      choice in patients with primary or secondary peritoneal surface malignancies. However the
      survival benefit is achieved at the cost of increased morbidity and mortality due to an
      extensive surgery and intraoperative chemo-therapy. Among complications infectious
      complications are the most common. The early diagnosis of a potential fatal infection is
      therefore crucial to ensure a good outcome in patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>C reactive protein (CRP) mg/l, receiver operating characteristic (ROC)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>CRS and HIPEC</arm_group_label>
    <description>Patients subjected to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) due to primary or secondary peritoneal malignancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRS and HIPEC</intervention_name>
    <description>During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy</description>
    <arm_group_label>CRS and HIPEC</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive adult patients (more than 18 years) subjected to cytoreductive surgery (CRS)
        and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) due to peritoneal malignancy at our
        institution.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive adult patients (more than 18 years) subjected to CRS and HIPEC due to
             peritoneal malignancy.

          -  Written informed consent by the participant after information about the research
             project

        Exclusion Criteria:

          -  No primary or secondary peritoneal surface malignancy

          -  No CRS and HIPEC

          -  Pregnancy

          -  Younger than 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuno Lehmann, Md. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Kuno Lehmann, Division of Visceral Surgery and Transplantation, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kuno Lehmann, MD, PhD</last_name>
    <phone>+41 44 255 23 04</phone>
    <email>kuno.lehmann@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dilmurodjon Eshmuminov, MD</last_name>
    <phone>+41 44 255 11 11</phone>
    <email>dilmurodjon.eshmuminov@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Visceral Surgery and Transplantation , University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuno Lehmann, MD, PhD</last_name>
      <phone>+41 44 255 23 04</phone>
      <email>kuno.lehmann@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Dilmurodjon Eshmuminov, MD</last_name>
      <phone>+41 44 255 11 11</phone>
      <email>dilmurodjon.eshmuminov@usz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009 Jun;249(6):900-7. doi: 10.1097/SLA.0b013e3181a45d86. Review.</citation>
    <PMID>19474692</PMID>
  </reference>
  <reference>
    <citation>Roviello F, Caruso S, Marrelli D, Pedrazzani C, Neri A, De Stefano A, Pinto E. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol. 2011 Mar;20(1):e38-54. doi: 10.1016/j.suronc.2010.09.002. Epub 2010 Dec 15. Review.</citation>
    <PMID>20888755</PMID>
  </reference>
  <reference>
    <citation>Klein HJ, Csordas A, Falk V, Slankamenac K, Rudiger A, Schönrath F, Rodriguez Cetina Biefer H, Starck CT, Graf R. Pancreatic stone protein predicts postoperative infection in cardiac surgery patients irrespective of cardiopulmonary bypass or surgical technique. PLoS One. 2015 Mar 20;10(3):e0120276. doi: 10.1371/journal.pone.0120276. eCollection 2015.</citation>
    <PMID>25793700</PMID>
  </reference>
  <reference>
    <citation>Younan R, Kusamura S, Baratti D, Cloutier AS, Deraco M. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008 Sep 15;98(4):253-7. doi: 10.1002/jso.21057. Review.</citation>
    <PMID>18726887</PMID>
  </reference>
  <reference>
    <citation>Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013 Jan;179(1):e133-9. doi: 10.1016/j.jss.2012.01.015. Epub 2012 Mar 10.</citation>
    <PMID>22480844</PMID>
  </reference>
  <reference>
    <citation>Sonnenberg EM, Reinke CE, Bartlett EK, Collier KT, Karakousis GC, Holena DN, Kelz RR. Wind, water, wound, walk--do the data deliver the dictum? J Surg Educ. 2015 Jan-Feb;72(1):164-9. doi: 10.1016/j.jsurg.2014.05.019. Epub 2014 Aug 12.</citation>
    <PMID>25131719</PMID>
  </reference>
  <results_reference>
    <citation>Lehmann K, Eshmuminov D, Slankamenac K, Kranzbühler B, Clavien PA, Vonlanthen R, Gertsch P. Where Oncologic and Surgical Complication Scoring Systems Collide: Time for a New Consensus for CRS/HIPEC. World J Surg. 2016 May;40(5):1075-81. doi: 10.1007/s00268-015-3366-0.</citation>
    <PMID>26669784</PMID>
  </results_reference>
  <results_reference>
    <citation>Capone A, Valle M, Proietti F, Federici O, Garofalo A, Petrosillo N. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol. 2007 Nov 1;96(6):507-13.</citation>
    <PMID>17708508</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peritoneal surface malignancies</keyword>
  <keyword>cytoreductive surgery</keyword>
  <keyword>hyperthermic intraperitoneal chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

